Literature DB >> 20167856

Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3.

Cristina Bianchi1, Silvia Bombelli, Francesca Raimondo, Barbara Torsello, Valentina Angeloni, Stefano Ferrero, Vitalba Di Stefano, Clizia Chinello, Ingrid Cifola, Lara Invernizzi, Paolo Brambilla, Fulvio Magni, Marina Pitto, Gianpaolo Zanetti, Paolo Mocarelli, Roberto A Perego.   

Abstract

Primary cell cultures from renal cell carcinoma (RCC) and normal renal cortex tissue of 60 patients have been established, with high efficiency (more than 70%) and reproducibility, and extensively characterized. These cultures composed of more than 90% of normal or tumor tubular cells have been instrumental for molecular characterization of Annexin A3 (AnxA3), never extensively studied before in RCC cells although AnxA3 has a prognostic relevance in some cancer and it has been suggested to be involved in the hypoxia-inducible factor-1 pathway. Western blot analysis of 20 matched cortex/RCC culture lysates showed two AnxA3 protein bands of 36 and 33 kDa, and two-dimensional Western blot evidenced several specific protein spots. In RCC cultures the 36-kDa isoform was significantly down-regulated and the 33-kDa isoform up-regulated. Furthermore, the inversion of the quantitative expression pattern of two AnxA3 isoforms in tumor cultures correlate with hypoxia-inducible factor-1alpha expression. The total AnxA3 protein is down-regulated in RCC cultures as confirmed also in tissues by tissue microarray. Two AnxA3 transcripts that differ for alternative splicing of exon III have been also detected. Real-time PCR quantification in 19 matched cortex/RCC cultures confirms the down-regulation of longer isoform in RCC cells. The characteristic expression pattern of AnxA3 in normal and tumor renal cells, documented in our primary cultures, may open new insight in RCC management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167856      PMCID: PMC2843458          DOI: 10.2353/ajpath.2010.090402

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

Review 1.  Regulation of renal calbindin-D28K.

Authors:  C Hemmingsen
Journal:  Pharmacol Toxicol       Date:  2000

2.  Identification and proteomic profiling of exosomes in human urine.

Authors:  Trairak Pisitkun; Rong-Fong Shen; Mark A Knepper
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

3.  Establishment and characterization of colon carcinoma and renal cell carcinoma primary cultures.

Authors:  B Trojaneck; S Niemitz; B Micka; P Lefterova; R Blasczyk; C Scheffold; D Huhn; I G Schmidt-Wolf
Journal:  Cancer Biother Radiopharm       Date:  2000-04       Impact factor: 3.099

4.  The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.

Authors:  G Li; K Passebosc-Faure; C Lambert; A Gentil-Perret; F Blanc; E Oosterwijk; J F Mosnier; C Genin; J Tostain
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

Review 5.  The cell cycle.

Authors:  R Baserga
Journal:  N Engl J Med       Date:  1981-02-19       Impact factor: 91.245

6.  Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

Authors:  Kevin J Turner; John W Moore; Adam Jones; Claire F Taylor; Darren Cuthbert-Heavens; Cheng Han; Russell D Leek; Kevin C Gatter; Patrick H Maxwell; Peter J Ratcliffe; David Cranston; Adrian L Harris
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

7.  Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells.

Authors:  Ursula Rescher; Antje Danielczyk; Arseni Markoff; Volker Gerke
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

8.  Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect.

Authors:  Richard D Unwin; Rachel A Craven; Patricia Harnden; Sarah Hanrahan; Nick Totty; Margaret Knowles; Ian Eardley; Peter J Selby; Rosamonde E Banks
Journal:  Proteomics       Date:  2003-08       Impact factor: 3.984

9.  Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors.

Authors:  Feras I Hawari; Farshid N Rouhani; Xinle Cui; Zu-Xi Yu; Caitriona Buckley; Maryann Kaler; Stewart J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

10.  Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma.

Authors:  Ali R Shekouh; Christopher C Thompson; Wendy Prime; Fiona Campbell; Jane Hamlett; C Simon Herrington; Nicholas R Lemoine; Tatjana Crnogorac-Jurcevic; Markus W Buechler; Helmut Friess; John P Neoptolemos; Stephen R Pennington; Eithne Costello
Journal:  Proteomics       Date:  2003-10       Impact factor: 3.984

View more
  16 in total

Review 1.  The role of annexin A3 playing in cancers.

Authors:  Na Wu; Shuqing Liu; Chunmei Guo; Zhijie Hou; Ming-Zhong Sun
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

2.  Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.

Authors:  Hiromi I Wettersten; A Ari Hakimi; Dexter Morin; Cristina Bianchi; Megan E Johnstone; Dallas R Donohoe; Josephine F Trott; Omran Abu Aboud; Steven Stirdivant; Bruce Neri; Robert Wolfert; Benjamin Stewart; Roberto Perego; James J Hsieh; Robert H Weiss
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

Review 3.  Role of annexin A3 in breast cancer (Review).

Authors:  Alpaslan Ozturk
Journal:  Mol Clin Oncol       Date:  2022-05-12

4.  Renal cell carcinoma primary cultures maintain genomic and phenotypic profile of parental tumor tissues.

Authors:  Ingrid Cifola; Cristina Bianchi; Eleonora Mangano; Silvia Bombelli; Fabio Frascati; Ester Fasoli; Stefano Ferrero; Vitalba Di Stefano; Maria A Zipeto; Fulvio Magni; Stefano Signorini; Cristina Battaglia; Roberto A Perego
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

5.  Three Dimensional Culture of Human Renal Cell Carcinoma Organoids.

Authors:  Cynthia A Batchelder; Michele L Martinez; Nadire Duru; Frederick J Meyers; Alice F Tarantal
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort.

Authors:  Ying Jin; Li-Ping Feng; Xiang Jiang; Yong-Xue Wang; Jie Yin; Zi-Ping Yang; Yan Li; Ling-Ya Pan
Journal:  J Cancer       Date:  2015-06-10       Impact factor: 4.207

7.  Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.

Authors:  Jie Yin; Xuedong Yan; Xin Yao; Yongli Zhang; Ying Shan; Ning Mao; Yili Yang; Lingya Pan
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

8.  Annexin A3 Knockdown Suppresses Lung Adenocarcinoma.

Authors:  Ying-Fu Liu; Qing-Qing Liu; Yue-Hua Zhang; Jing-Hua Qiu
Journal:  Anal Cell Pathol (Amst)       Date:  2016-11-22       Impact factor: 2.916

9.  Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study.

Authors:  Tao Zhou; Yong Li; Li Yang; Tiantian Tang; Lina Zhang; Jiajie Shi
Journal:  Biomed Res Int       Date:  2017-04-13       Impact factor: 3.411

10.  The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.

Authors:  Cristina Bianchi; Chiara Meregalli; Silvia Bombelli; Vitalba Di Stefano; Francesco Salerno; Barbara Torsello; Sofia De Marco; Giorgio Bovo; Ingrid Cifola; Eleonora Mangano; Cristina Battaglia; Guido Strada; Giuseppe Lucarelli; Robert H Weiss; Roberto A Perego
Journal:  Oncotarget       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.